25. Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents. But patients who have received prior treatment with anti CTLA-4 may be enrolled, provided the following requirements are met: (1). Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose; (2). No history of severe immune-related adverse effects from anti-CTLA 4 (NCI CTCAE Grade 3 and 4)